Fludarabine
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
University of Medicine and Dentistry of New JerseySmall moleculePhase 3Dormant
BB
71/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 59/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CYCLOSPORIN A National Cancer Institute (NCI) | Phase 3 | BBB |
Monomethyl Fumarate University of Medicine and Dentistry of New Jersey | Phase 3 | BB |
Cyclophosphamide OHSU Knight Cancer Institute | Phase 3 | BB |
Cediranib National Cancer Institute (NCI) | Phase 3 | BB |
METHOTREXATE National Cancer Institute (NCI) | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →